Skip to main content

Table 5 Multivariable linear regression models of the association between treatment with proton-pump inhibitor (PPI) and/or H2 blocker and slopes of lung function, in those with and without gastroesophageal reflux disease (GERD). ß coefficients reflect the mean differences in the row outcome of interest between those with treatment with PPI and/or H2 blocker, compared to those not receiving treatment

From: Impact of gastroesophageal reflux on longitudinal lung function and quantitative computed tomography in the COPDGene cohort

 

Adjusted ß Estimate

(95% CI)

GERD (n = 960)

 FEV1 (mL/year)

−6.61 (−11.9, − 1.36)

 FVC (mL/year)

−9.26 (− 17.2, − 1.28)

No GERD (n = 221)

 FEV1 (mL/year)

6.38 (−3.04, 15.8)

 FVC (mL/year)

3.97 (−7.66, 15.6)

  1. Adjustment was made for the following variables: age, sex, race, smoked between phase I and II, BMI, clinical center, FEV1% predicted at Phase I, and acute exacerbation ≥1 between phase I and II
  2. PPI include esomeprazole, lansoprazole, pantoprazole, omeprazole, rabeprazole
  3. H2 blocker include cimetidine, ranitidine, famotidine, nizatidine
  4. PPI and/or H2 blocker (59.8%), PPI (52.4%), H2 blocker (13.0%)
  5. Abbreviations: GERD gastroesophageal reflux disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity. PPI proton pump inhibitor, H2blocker histamine receptor-2 blocker and CI confidence interval